ArticleInternational journal of social determinants of health and health services2026
Reframing the Overdose Crisis: Stigma, Industry Influence, and the Politics of Abuse-Deterrent Opioids.
Article in International journal of social determinants of health and health services, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Purdue's development of abuse-deterrent formulation opioids as a response to market competition: An industry documents analysis.SSM. Qualitative research in health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Between 2013 and 2017, Canadian federal policymakers grappled with mandating abuse-deterrent formulations (ADFs) for oxycodone products as a response to the overdose crisis. Marketed as a safeguard against misuse and diversion, ADFs promised a technological fix to opioid-related harms, yet their population-level effectiveness remained contested. This study systematically analyzes federal parliamentary debates and committee hearings, identifying key arguments in framings to support or oppose ADF mandates. Proponents framed the crisis through the lens of individual misuse, positioning ADFs as pharmaceutical safeguards that protected "legitimate" patients while curbing illicit opioid use. Opponents challenged ADFs' effectiveness, highlighted Purdue Pharma's role in the crisis, and warned of unintended consequences, including shifts to more dangerous illicit markets. These discursive struggles reinforced a bifurcation between "legitimate" and "illegitimate" opioid use, shaping perceptions of responsibility, medical necessity, and the scope of appropriate intervention. Divergent framings reflected deeper ideological fissures over the etiology of the overdose crisis and who should be considered a justifiable opioid patient. By demonstrating how ADF debates entrenched a dichotomy between acceptable and unacceptable opioid use, this study advances theories of problem framing to demonstrate how policy debates actively shape regulatory paradigms and the boundaries of acceptable government intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.